For research use only. Not for therapeutic Use.
FAAH-IN-6 (compound 21d) is a potent, orally active and cross the blood-brain barrier fatty acid amide hydrolase (FAAH) inhibitor with IC50s of 0.72, 0.28 nM for hFAAH, rFAAH, respectively. FAAH-IN-6 shows dose-dependent analgesic efficacy in animal models of both neuropathic and inflammatory pain[1].
FAAH-IN-6 (compound 21d) (1-10 mg/kg; p.o.) shows significantly ameliorates tactile allodynia in a dose-dependent fashion in SNI-induced neuropathic pain rats model[1].
FAAH-IN-6 (3-10 mg/kg; p.o.) shows significantly ameliorates tactile allodynia of the ipsilateral hind paw in CFA-induced inflammatory pain model[1].
| Catalog Number | I011132 |
| CAS Number | 1143578-94-2 |
| Synonyms | 4-[4-(3,4-difluorophenyl)pyrimidin-2-yl]-N-pyridazin-3-ylpiperazine-1-carboxamide |
| Molecular Formula | C19H17F2N7O |
| Purity | ≥95% |
| InChI | InChI=1S/C19H17F2N7O/c20-14-4-3-13(12-15(14)21)16-5-7-22-18(24-16)27-8-10-28(11-9-27)19(29)25-17-2-1-6-23-26-17/h1-7,12H,8-11H2,(H,25,26,29) |
| InChIKey | JCWVFSJNIBAGQN-UHFFFAOYSA-N |
| SMILES | C1CN(CCN1C2=NC=CC(=N2)C3=CC(=C(C=C3)F)F)C(=O)NC4=NN=CC=C4 |
| Reference | [1]. Kono M, et al. Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors. Bioorg Med Chem. 2014 Feb 15;22(4):1468-78. |
